ClinicalTrials.gg
CompletedNCT03700320Updated Jun 15, 2021Results posted

Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

A Phase 3 interventional study of Standard of Care (SOC) Migraine Preventive Medication and Atogepant in Episodic Migraine, sponsored by Allergan. Completed at 112 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-06-15.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
744
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing atogepant in Migraine Disorders — 6 open to participants now, 7 under way, 4 of them phase 3. atogepant · Migraine Disorders.

Enrollment
6th of 21
744 · median 468
Started
2018
with 1 other
Phase 3
15 of 21
3 open now
Registered
2nd of 21
by date
Lead sponsor
7 of 21
Allergan

Among the 21 studies testing atogepant in Migraine Disorders, this one is the 6th largest by enrollment, is one of 2 that started in 2018, is one of 15 in phase 3, and was the 2nd registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing atogepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About atogepant

atogepant: first FDA approval 2021 (QULIPTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing atogepant in Migraine Disorders, or all of them as a file.
02

Study summary

This study will evaluate safety and tolerability of treatment with atogepant for the prevention of episodic migraine over the course of one year.

03

Conditions studied

  • Episodic Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written and participant privacy information (e.g., written authorization for use and release of health and research study information) obtained from the participant prior to initiation of any study-specific procedures.
  • Participant is a candidate to be prescribed at least one of the protocol-defined acceptable oral SOC migraine prevention medications and the participant is willing to accept SOC treatment.
  • Participants must be using a medically acceptable and effective method of during the course of the entire study,
  • At least a 1-year history of migraine with or without aura consistent with a diagnosis
  • Age of the participant at the time of migraine onset \< 50 years
  • History of 4 to 14 migraine days per month on average in the 3 months prior to Visit 1

Exclusion criteria

Exclusion Criteria:

  • Difficulty distinguishing migraine headaches from tension-type or other headaches
  • Has a history of migraine accompanied by diplopia or decreased level of consciousness or retinal migraine
  • Has a current diagnosis of chronic migraine (CM), new persistent daily headache, trigeminal autonomic cephalgia (e.g., cluster headache), or painful cranial neuropathy
  • ≥ 15 headache days per month on average across the 3 months prior to Visit 1
  • Usage of opioids or barbiturates > 2 days/month, triptans or ergots ≥ 10 days/month, or simple analgesics (e.g., aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen) ≥ 15 days/month in the 3 months prior to Visit 1 per investigator's judgment, or during the baseline period. For all participants, barbiturates are excluded 30 days prior to screening and during the baseline period. For participants randomized to atogepant, barbiturates are excluded through the duration of the study as well
  • Female participant is pregnant, planning to become pregnant during the course of the study, or currently lactating. Women of must have a negative urine pregnancy test
  • Any hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal (GI), or neurologic disease
  • Hypertension as defined by sitting systolic blood pressure (BP) > 160 millimeter of mercury (mm Hg) or sitting diastolic BP > 100 mm Hg at Visits 1 or Visit 2. Vital sign measurements that exceed these limits may be repeated only once.
  • At Visit 1, a user of recreational or illicit drugs or has had a history within the past year of drug or alcohol abuse or dependence
  • History of any GI prior procedures or GI conditions (e.g., diarrhea syndromes, inflammatory bowel disease) that may affect the absorption or metabolism of atogepant; participants with prior gastric bariatric interventions (e.g., Lap Band) which have been reversed are not excluded.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
744 participants (actual)

Study arms

  • Active comparator
    Oral SOC Migraine Preventive Medication

    Oral standard of care (SOC) medication recognized as safe and effective for the prevention of migraine, based on investigator's judgement in consultation with the participant.

    Drug: Standard of Care (SOC) Migraine Preventive Medication

  • Experimental
    Atogepant 60 mg

    Atogepant 60 mg tablet taken orally, once daily for 52 weeks.

    Drug: Atogepant

Interventions

  • DrugStandard of Care (SOC) Migraine Preventive Medication

    Standard of care medication selected based on investigator's judgement, recognized as safe and effective for the prevention of migraine.

  • Atogepant tablets taken orally, once daily for 52 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least 1 Treatment Emergent Adverse Event (TEAE)

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE is an AE that occurs or worsens after receiving investigational study drug.

    Time frame: From first dose up to the end of study (median treatment of 52 weeks) + 4 weeks follow-up

Secondary outcomes

  1. Percentage of Participants With Clinically Significant Laboratory Values as Assessed by the Investigator

    Laboratory tests included tests of hematology, chemistry, and urinalysis. The investigator determined if the results were potentially clinically significant (PCS). Only categories with at least one participant are reported.

    Time frame: From first dose up to the end of study (median treatment of 52 weeks) + 4 weeks follow-up

  2. Percentage of Participants With Clinically Significant Electrocardiogram (ECG) Findings as Assessed by the Investigator

    A standard 12-lead ECG was performed. The investigator determined if the result was potentially clinically significant. Only categories with at least one participant are reported.

    Time frame: Up to Week 52

  3. Percentage of Participants With Clinically Significant Vital Sign Measurements as Assessed by the Investigator

    Vital sign measurements included sitting and standing blood pressure (BP), sitting and standing pulse rate, respiratory rate, temperature, and body weight. The investigator determined if the results were clinically significant. Only categories with at least one participant are reported.

    Time frame: From first dose up to the end of study (median treatment of 52 weeks + 4 weeks follow-up)

  4. Number of Participants With Most Severe Columbia-Suicide Severity Rating Scale (C-SSRS) Assessing Suicidal Ideation or Suicidal Behavior

    The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. (Minimum total score 0, maximum total score 5; higher total scores indicate more suicidal ideation and/or suicidal behavior). Only the most severe suicidal ideation and the most severe suicidal behavior counted during the treatment period for at least 1 participant are reported.

    Time frame: Up to Week 52

07

Results

Posted Jun 15, 2021

Participant flow

Participant flow — Overall Study
MilestoneOral SOC Migraine Preventive MedicationAtogepant 60 mg
Started198546
Safety population; received treatment196543
Entered safety follow-up159472
Completed136373
Not completed62173
Withdrew: Adverse event531
Withdrew: Lack of efficacy25
Withdrew: Withdrawal by subject2975
Withdrew: Lost to follow-up1623
Withdrew: Pregnancy24
Withdrew: Protocol deviation731
Withdrew: Non-compliance with study drug13
Withdrew: Reason not specified01

Outcome measures

PrimaryPercentage of Participants With at Least 1 Treatment Emergent Adverse Event (TEAE)

An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE is an AE that occurs or worsens after receiving investigational study drug.

Time frame:
From first dose up to the end of study (median treatment of 52 weeks) + 4 weeks follow-up
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 1 Treatment Emergent Adverse Event (TEAE)
percentage of participantsOral SOC Migraine Preventive MedicationAtogepant 60 mg
Percentage of Participants With at Least 1 Treatment Emergent Adverse Event (TEAE)78.667.0
SecondaryPercentage of Participants With Clinically Significant Laboratory Values as Assessed by the Investigator

Laboratory tests included tests of hematology, chemistry, and urinalysis. The investigator determined if the results were potentially clinically significant (PCS). Only categories with at least one participant are reported.

Time frame:
From first dose up to the end of study (median treatment of 52 weeks) + 4 weeks follow-up
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Significant Laboratory Values as Assessed by the Investigator
percentage of participantsOral SOC Migraine Preventive MedicationAtogepant 60 mg
Eosinophils Absolute Cell Count (10^9/liter (L)): >2.0 × upper limit of normal (ULN)0.00.6
Hematocrit (RATIO): <0.9 × lower limit of normal (LLN)1.61.7
Hematocrit (RATIO): >1.1 × ULN0.00.2
Hemoglobin (gram (g)/L): <0.9 × LLN3.33.1
Lymphocytes Absolute Cell Count (10^9/L): <0.7 × LLN0.50.8
Lymphocytes Absolute Cell Count (10^9/L): >1.3 × ULN0.50.2
Monocytes Absolute Cell Count (10^9/L): <0.5 × LLN1.10.2
Neutrophils Absolute Cell Count (10^9/L): <0.7 × LLN2.12.3
Neutrophils Absolute Cell Count (10^9/L): >1.3 × ULN4.87.1
Platelet Count (Thrombocytes) (10^9/L): >1.5 × ULN0.50.2
Red Blood Cell Count (10^12/L): <0.9 × LLN3.22.1
White Blood Cell Count (10^9/L): <0.9 × LLN3.24.6
White Blood Cell Count (10^9/L): >1.5 × ULN1.10.6
Alanine Aminotransferase (serum glutamic-pyruvic transaminase (SGPT)) (Unit (U)/L): ≥3.0 × ULN1.61.9
Aspartate Aminotransferase (serum glutamic-oxaloacetic transaminase (SGOT)) (U/L): ≥3.0 × ULN2.11.5
Bicarbonate (HCO3) (millimole (mmol)/L): <0.9 × LLN1.60.8
Bilirubin, Total (micromole (umol)/L): ≥1.5 × ULN0.00.8
Blood Urea Nitrogen (mmol/L): >1.5 × ULN0.50.4
Creatine Kinase (U/L): >2.0 × ULN14.19.1
Creatinine (umol/L): >1.5 × ULN1.10.4
Glomerular Filtration Rate(GFR) Estimated Calculation:<60 milliliter(mL)/minute(min)/1.73 meter(m)^215.215.9
Glucose, Non-fasting (mmol/L): <0.8 × LLN5.34.2
Glucose, Non-fasting (mmol/L): >2.0 × ULN2.10.8
Lactate Dehydrogenase (U/L): >3.0 × ULN0.00.4
Phosphorus (mmol/L): <0.9 × LLN2.12.6
Phosphorus (mmol/L): >1.1 × ULN0.00.2
Potassium (mmol/L): <0.9 × LLN1.10.8
Potassium (mmol/L): >1.1 × ULN4.35.1
Protein, Total (g/L): <0.9 × LLN3.21.5
Uric Acid (Urate) (umol/L): >1.2 × ULN1.61.1
Urine Glucose At Least 1+4.33.0
Urine Protein: At Least 1+26.227.4
SecondaryPercentage of Participants With Clinically Significant Electrocardiogram (ECG) Findings as Assessed by the Investigator

A standard 12-lead ECG was performed. The investigator determined if the result was potentially clinically significant. Only categories with at least one participant are reported.

Time frame:
Up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Significant Electrocardiogram (ECG) Findings as Assessed by the Investigator
percentage of participantsOral SOC Migraine Preventive MedicationAtogepant 60 mg
PR Interval, Single Beat millisecond (msec): ≥2500.00.2
QTcB Interval, Single Beat (msec): Increase >60 from Baseline (BL)0.60.4
QTcF Interval, Single Beat (msec): Increase >60 from BL0.60.0
SecondaryPercentage of Participants With Clinically Significant Vital Sign Measurements as Assessed by the Investigator

Vital sign measurements included sitting and standing blood pressure (BP), sitting and standing pulse rate, respiratory rate, temperature, and body weight. The investigator determined if the results were clinically significant. Only categories with at least one participant are reported.

Time frame:
From first dose up to the end of study (median treatment of 52 weeks + 4 weeks follow-up)
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Significant Vital Sign Measurements as Assessed by the Investigator
percentage of participantsOral SOC Migraine Preventive MedicationAtogepant 60 mg
Systolic Blood Pressure (SBP) Sitting (millimeter of mercury(mmHg)):≤90 and Decrease of ≥20 from BL3.72.6
SBP Sitting (mmHg): ≥180 and Increase of ≥20 from BL0.00.4
SBP Standing (mmHg): ≤90 and Decrease of ≥20 from BL5.83.4
SBP Standing (mmHg): ≥180 and Increase of ≥20 from BL0.00.6
Standing - Sitting SBP (mmHg): ≤-2013.811.4
Diastolic Blood Pressure (DBP) Sitting (mmHg): ≤50 and Decrease of ≥15 from BL3.20.6
DBP Sitting (mmHg): ≥105 and Increase of ≥15 from BL1.12.3
DBP Standing (mmHg): ≤50 and Decrease of ≥15 from BL1.10.9
DBP Standing (mmHg): ≥105 and Increase of ≥15 from BL5.84.0
Standing - Sitting DBP (mmHg): ≤-1510.18.7
Pulse Rate (PR) Sitting (beats/min): ≤50 and Decrease of ≥15 from BL1.61.1
PR Standing (beats/min): ≤50 and Decrease of ≥15 from BL0.00.2
PR Standing (beats/min): ≥120 and Increase of ≥15 from BL2.61.3
Standing - Sitting PR (beats/min): ≥256.310.0
Weight (kg): Decrease of ≥7% from BL14.724.1
Weight (kg): Increase of ≥7% from BL12.67.3
SecondaryNumber of Participants With Most Severe Columbia-Suicide Severity Rating Scale (C-SSRS) Assessing Suicidal Ideation or Suicidal Behavior

The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. (Minimum total score 0, maximum total score 5; higher total scores indicate more suicidal ideation and/or suicidal behavior). Only the most severe suicidal ideation and the most severe suicidal behavior counted during the treatment period for at least 1 participant are reported.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Most Severe Columbia-Suicide Severity Rating Scale (C-SSRS) Assessing Suicidal Ideation or Suicidal Behavior
ParticipantsOral SOC Migraine Preventive MedicationAtogepant 60 mg
Suicidal Ideation (SI): Wish to be Dead40
SI: Non-Specific Active Suicidal Thoughts12
SI: Active SI with Some Intent to Act, Without Specific Plan01
SI: Active SI With Specific Plan and Intent02
Suicidal Behavior (SB): Actual Attempt02

Adverse events

Collected over From first dose up to the end of study (median treatment of 52 weeks + 4 weeks follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral SOC Migraine Preventive Medication0/198 (0%)7/196 (3.6%)91/196 (46.4%)
Atogepant 60 mg2/546 (0.4%)24/543 (4.4%)197/543 (36.3%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventOral SOC Migraine Preventive MedicationAtogepant 60 mg
Non-cardiac chest painGeneral disorders2/1960/543
OsteonecrosisMusculoskeletal and connective tissue disorders1/1960/543
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1960/543
Colon cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1960/543
Device malfunctionProduct Issues1/1960/543
Suicidal ideationPsychiatric disorders1/1960/543
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1721/479
Ovarian cystReproductive system and breast disorders0/1721/479
Uterine haemorrhageReproductive system and breast disorders0/1721/479
VertigoEar and labyrinth disorders0/1961/543
Most frequent other events
Most frequent other events
EventOral SOC Migraine Preventive MedicationAtogepant 60 mg
Upper respiratory tract infectionInfections and infestations24/19656/543
DizzinessNervous system disorders22/19617/543
ConstipationGastrointestinal disorders6/19639/543
NauseaGastrointestinal disorders12/19634/543
FatigueGeneral disorders12/19614/543
ParaesthesiaNervous system disorders12/1968/543
Weight increasedInvestigations11/1967/543
AnxietyPsychiatric disorders11/19615/543
Urinary tract infectionInfections and infestations9/19628/543
NasopharyngitisInfections and infestations10/19624/543

Baseline characteristics

Safety Population included all participants who received ≥1 dose of study intervention.

Age, Continuous
Age, Continuous(years)Oral SOC Migraine Preventive MedicationAtogepant 60 mgTotal
Mean41.1 ± 12.0942.5 ± 12.0342.2 ± 12.05
Sex: Female, Male
Sex: Female, Male(Participants)Oral SOC Migraine Preventive MedicationAtogepant 60 mgTotal
Female172479651
Male246488
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Oral SOC Migraine Preventive MedicationAtogepant 60 mgTotal
Hispanic or Latino2983112
Not Hispanic or Latino166460626
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Oral SOC Migraine Preventive MedicationAtogepant 60 mgTotal
American Indian or Alaska Native033
Asian51217
Native Hawaiian or Other Pacific Islander224
Black or African American38100138
White145416561
More than one race51015
Unknown or Not Reported101
08

Study locations

112 sites
  • Clinical Research Advantage, Inc./Simon Williamson Clinic, PC
    Birmingham, Alabama 35211, United States
  • Achieve Clinical Research, LLC
    Birmingham, Alabama 35216, United States
  • Synexus Clinical Research US, Inc./East Valley Family Physicians PLC
    Chandler, Arizona 85224, United States
  • Synexus Clinical Research US, Inc./Desert Clinical Research, LLC
    Mesa, Arizona 85213, United States
  • Synexus Clinical Research US, Inc./Central Phoenix Medical Clinic, LLC
    Phoenix, Arizona 85020, United States
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Hope Clinical Research
    Canoga Park, California 91303, United States
  • Pharmacology Research Institute
    Encino, California 91316, United States
  • Sun Valley Research Center, Inc.
    Imperial, California 92251, United States
  • Irvine Center for Clinical Research
    Irvine, California 92614, United States
  • Grossmont Center for Clinical Research
    La Mesa, California 91942, United States
  • Synergy San Diego
    Lemon Grove, California 91945, United States
  • Collaborative Neuroscience Network, LLC.
    Long Beach, California 90806, United States
  • Pharmacology Research Institute
    Los Alamitos, California 90720, United States
  • Pacific Research Partners, LLC
    Oakland, California 94607, United States
  • Excell Research, Inc.
    Oceanside, California 92056, United States
  • Desert Valley Research
    Redlands, California 92374, United States
  • Medical Center for Clinical Research
    San Diego, California 92108, United States
  • California Research Foundation
    San Diego, California 92123-1881, United States
  • Artemis Institute for Clinical Research
    San Marcos, California 92078, United States
  • California Medical Clinic for Headache
    Santa Monica, California 90404, United States
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
  • Synexus Clinical Research US, Inc.
    Vista, California 92083, United States
  • Diablo Clinical Research, Inc
    Walnut Creek, California 94598, United States
  • Delta Waves, Inc.
    Colorado Springs, Colorado 80918, United States
  • Advanced Neurosciences Research, LLC
    Fort Collins, Colorado 80528, United States
  • MD Clinical
    Hallandale Beach, Florida 33009, United States
  • Infinity Clinical Research
    Hollywood, Florida 33024, United States
  • Clinical Neuroscience Solutions
    Jacksonville, Florida 32256, United States
  • Health Awareness, Inc.
    Jupiter, Florida 33458, United States
  • Meridien Research
    Maitland, Florida 32751, United States
  • Well Pharma Medical Research, Corp.
    Miami, Florida 33173, United States
  • Sensible Healthcare LLC
    Ocoee, Florida 34761, United States
  • Clinical Neuroscience Solutions, Inc
    Orlando, Florida 32801, United States
  • Bioclinica Research
    Orlando, Florida 32806, United States
  • Infinity Clinical Research LLC
    Sunrise, Florida 33351, United States
  • Meridien Research
    Tampa, Florida 33634, United States
  • Premiere Research Institute
    West Palm Beach, Florida 33407, United States
  • Palm Beach Research Center
    West Palm Beach, Florida 33409, United States
  • Synexus Clinical Research US, Inc.
    Atlanta, Georgia 30328, United States
  • Atlanta Center for Clinical Research
    Atlanta, Georgia 30331, United States
  • Columbus Regional Research Institute
    Columbus, Georgia 31904, United States
  • iResearch Atlanta
    Decatur, Georgia 30030, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • Northwest Clinical Trials
    Boise, Idaho 83704, United States
  • Advanced Clinical Research
    Meridian, Idaho 83642, United States
  • Evanston Premier Healthcare Research LLC
    Evanston, Illinois 60201, United States
  • MidAmerica Neuroscience Research Foundation dba Rowe Neurology Institute
    Lenexa, Kansas 66214, United States
  • Kansas Institute of Research
    Overland Park, Kansas 66211, United States
  • Phoenix Medical Research, Inc.
    Prairie Village, Kansas 66208, United States
  • Kentucky Pediatric Research
    Bardstown, Kentucky 40004, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • New Orleans Center for Clinical Research
    New Orleans, Louisiana 70119, United States
  • Community Clinical Research Network
    Marlborough, Massachusetts 01752, United States
  • Michigan Headache & Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • Beyer Research
    Kalamazoo, Michigan 49009, United States
  • Clinical Research Institute, Inc.
    Minneapolis, Minnesota 55402, United States
  • Olive Branch Family Medical Center
    Olive Branch, Mississippi 38654, United States
  • ClinVest
    Springfield, Missouri 65810, United States
  • Meridian Clinical Research, LLC
    Norfolk, Nebraska 68701, United States
  • Quality Clinical Research
    Omaha, Nebraska 68114, United States
  • Meridian Clinical Research, LLC
    Omaha, Nebraska 68134, United States
  • Synexus Clinical Research US, Inc
    Omaha, Nebraska 68144, United States
  • Altea Research Institute
    Las Vegas, Nevada 89102, United States
  • Hassman Research Institutes
    Berlin, New Jersey 08009, United States
  • Amici Clinical Research
    Raritan, New Jersey 08869, United States
  • Princeton Center for Clinical Research
    Skillman, New Jersey 08558, United States
  • Bio Behavioral Health
    Toms River, New Jersey 08755, United States
  • Albuquerque Clinical Trials, Inc.
    Albuquerque, New Mexico 87102, United States
  • Dent Neurosciences Research Center
    Amherst, New York 14226, United States
  • Regional Clinical Research, Inc.
    Endwell, New York 13760, United States
  • Synexus Clinical Research US, Inc.
    Jamaica, New York 11432, United States
  • Central New York Clinical Research
    Manlius, New York 13104, United States
  • Rochester Clinical Research
    Rochester, New York 14609, United States
  • Upstate Clinical Research Associates, LLC
    Williamsville, New York 14221, United States
  • Plains Clinical Medical Clinic, LLC
    Fargo, North Dakota 58104, United States
  • Synexus Clinical Research US, Inc.
    Akron, Ohio 44311, United States
  • Synexus Clinical Research US, Inc.
    Cincinnati, Ohio 45236, United States
  • Rapid Medical Research, Inc.
    Cleveland, Ohio 44122, United States
  • Ohio Clinical Research, LLC
    Willoughby Hills, Ohio 44094, United States
  • IPS Research Company
    Oklahoma City, Oklahoma 73106, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Summit Research Network
    Portland, Oregon 97210, United States
  • Oregon Center for Clinical Investigations, Inc.
    Salem, Oregon 97301, United States
  • Lehigh Center for Clinical Research
    Allentown, Pennsylvania 18104, United States
  • Suburban Research Associates
    Media, Pennsylvania 19063, United States
  • Clinical Research of Philadelphia, LLC
    Philadelphia, Pennsylvania 19114, United States
  • Frontier Clinical Research, LLC
    Scottdale, Pennsylvania 15683, United States
  • Frontier Clinical Research, LLC
    Smithfield, Pennsylvania 15478, United States
  • Radiant Research, Inc.
    Anderson, South Carolina 29621, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • Meridian Clinical Research, LLC
    Dakota Dunes, South Dakota 57049, United States
  • Volunteer Research Group
    Knoxville, Tennessee 37920, United States
  • CNS Healthcare - Memphis
    Memphis, Tennessee 38119, United States
  • Trinity Clinical Research
    Tullahoma, Tennessee 37388, United States
  • FutureSearch Trials of Neurology
    Austin, Texas 78731, United States
  • Tekton Research, Inc
    Austin, Texas 78745, United States
  • DiscoveResearch, Inc.
    Bryan, Texas 77802, United States
  • FutureSearch Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • Earle Research
    Houston, Texas 77058, United States

Showing the first 100 of 112 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Boinpally R, McNamee B, Yao L, Butler M, McGeeney D, Borbridge L, Periclou A. A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single-Dose, Phase 1 Crossover Trial. Clin Pharmacol Drug Dev. 2021 Sep;10(9):1099-1107. doi: 10.1002/cpdd.940. Epub 2021 May 4. PubMed 33942560 ↗
  • Min KC, Kraft WK, Bondiskey P, Colon-Gonzalez F, Liu W, Xu J, Panebianco D, Mixson L, Dockendorf MF, Matthews CZ, Boinpally R. Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults. Clin Transl Sci. 2021 Mar;14(2):599-605. doi: 10.1111/cts.12917. Epub 2020 Nov 24. PubMed 33142014 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in May 2020, 19 months.

Results were first posted in Jun 2021, 1 year after primary completion.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 19 months is close to that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2018
First posted
Oct 9, 2018
StartActual
Oct 8, 2018
Primary completionActual
May 21, 2020
CompletionActual
May 21, 2020
Results first posted
Jun 15, 2021
Last update
Jun 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03700320
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Oct 9, 2018
Start date
Oct 8, 2018
Primary completion
May 21, 2020
Completion
May 21, 2020
Results posted
Jun 15, 2021
Last update
Jun 15, 2021

Study contacts

Joel Trugman, MD
study director · Allergan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atogepant

Start the discussion